SHANGHAI, Dec. 22, 2024 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovatio...
* CS5001 is so far the first anti-ROR1 ADC known to show clinical anti-tumor activity in both sol...
* This approval marks the second international marketing authorization for sugemalimab outside of...
* Total revenue of RMB 254.2 million for 2024 H1; achieving first-time profitability with cash re...
* Sugemalimab becomes the world's first anti-PD-L1 monoclonal antibody (mAb) approved inEurope for...
* EMA CHMP recommendation is based on the results of a Phase 3 clinical trial (GEMSTONE-302) demo...
* CS5001 is the first known ROR1 antibody-drug conjugate (ADC) to demonstrate clinical anti-tumor...
* Total revenue for 2023 was RMB463.8 million, with commercial revenue of RMB 368.1 million * H...
* Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of g...
* The deal enables CStone to prioritize its resources to focus on the development of first-in-clas...
* Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for use in combination...
* CStone to grant 3SBio exclusive rights for the development, registration, manufacturing, and co...
* Sugemalimab is the world's first anti-PD-1/PD-L1 monoclonal antibody approved for relapsed or r...
* The total revenue was RMB 261.5 million for the six months ended June 30, 2023. The sales of ph...
* The approval for the first-line treatment of RET fusion-positive non-small cell lung cancer mar...
* The total revenue for 2022 was RMB 481.4 million, with commercial revenue of RMB 394.1 million, ...
* This supplementary new drug application was filed for the fourth indication for sugemalimab inC...
* Sugemalimab became the first anti-PD-L1 monoclonal antibody that achieved positive results in th...
* This is the third supplemental new drug application (NDA) that CStone has submitted for sugemal...
SUZHOU, China, Aug. 25, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leadi...